Jonathan Edelman, senior vice president of CSL’s vaccines innovation unit, said the approval “marks a significant milestone” ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

BTIG raised the firm’s price target on Arcturus Therapeutics (ARCT) to $48 from $41 and keeps a Buy rating on the shares. The Kostaive ...

Also in Europe, officials signed off on CSL and Arcturus Therapeutics' self-amplifying mRNA COVID-19 vaccine, Kostaive, for use in individuals ages 18 and older. The approval is based on results ...

KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA ...

Arcturus Therapeutics and CSL's COVID-19 vaccine Kostaive is the first in the new sa-mRNA class to be approved for marketing in the EU. The importance of biosimilars only continues to grow ...

Click here to see the full list of 230 stocks from our US High Growth Tech and AI Stocks screener. Let's uncover some gems from our specialized screener. Capricor Therapeutics Simply Wall St ...

The United States market has shown a positive trajectory, climbing 1.5% in the past week and achieving a 22% increase over the last year, with earnings projected to grow by 15% annually in the coming ...

The beauty of quantum computing is that it is poised to power groundbreaking discoveries that would dramatically alter what we, as a nation, and globally, are capable of achieving. It has the ...